Oversulfated chondroitin sulfate interaction with heparin-binding proteins: New insights into adverse reactions from contaminated heparins
Tóm tắt
Từ khóa
Tài liệu tham khảo
Capila, 2002, Heparin-protein interactions, Angew Chem Int Ed Engl, 41, 391, 10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B
Linhardt, 1997, Heparin oligosaccharides: new analogues-development and applications, 277
Brister SJ, Buchanan MR, Griffin CC, Van Gorp CL, Linhardt RJ. Dermatan disulfate, an inhibitor of thrombin and complement activation. U.S. Patent 5,922,690; 1999.
Linhardt, 1991, Heparin: an important drug enters its seventh decade, Chem Ind, 2, 45
Linhardt, 1999, Production and chemical processing of low molecular weight heparins, Semin Thromb Hemost, 25, 5
Volpi, 2006
Maruyama, 1998, Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation, Carbohydr Res, 306, 35, 10.1016/S0008-6215(97)10060-X
Kishimoto, 2008, Contaminated heparin associated with adverse clinical events and activation of the contact system, N Engl J Med, 358, 2457, 10.1056/NEJMoa0803200
Guerrini, 2008, Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events, Nat Biotechnol, 26, 669, 10.1038/nbt1407
Carranza, 2008, Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate, Blood Coag Fibrin, 19, 483, 10.1097/MBC.0b013e3282f2a99e
Moreau, 2005, The kallikrein–kinin system: current and future pharmacological targets, J Pharmacol Sci, 99, 6, 10.1254/jphs.SRJ05001X
Hamad, 2008, Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets, J Thromb Haemost, 6, 1413, 10.1111/j.1538-7836.2008.03034.x
Edens, 1993, Heparin is not just an anticoagulant anymore: six and one-half decades of studies on the ability of heparin to regulate complement activation, Complement Profiles, 1, 96
Yu, 2005, Kinetic studies on the interaction of heparin and complement proteins using surface plasmon resonance, Biochem Biophys Acta, 1726, 168, 10.1016/j.bbagen.2005.08.003
Nadkarni, 1996, Preparation and biological activity of N-sulfonated chondroitin and dermatan sulfate derivatives, Carbohydr Res, 290, 87, 10.1016/0008-6215(96)00129-2
Gozzo, 2002, Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation, Immunopharmacology, 2, 1861, 10.1016/S1567-5769(02)00145-5
Renne, 2005, Local bradykinin formation is controlled by glycosaminoglycans, J Immunol, 175, 3377, 10.4049/jimmunol.175.5.3377
Zhang, 2008, Oversulfated chondroitin sulfate: impact of a heparin impurity associated with adverse clinical events on low molecular weight heparin preparation, J Med Chem, 51, 5498, 10.1021/jm800785t
Sanchez, 1998, Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin, Thromb Res, 89, 41, 10.1016/S0049-3848(97)00310-1
Hoppensteadt, 2008, Contaminant in the recalled unfractionated heparin preparations: where is the problem?, Clin Appl Thromb Hemost, 14, 261, 10.1177/1076029608317932
Chen, 2005, Enzymatic redesigning of biological active heparan sulfate, J Biol Chem, 280, 42817, 10.1074/jbc.M504338200
Linhardt, 1991, Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities, Biochem Pharmacol, 42, 1609, 10.1016/0006-2952(91)90431-4
Samuel, 1992, Human factor XII (Hageman factor) autoactivation by dextran sulfate, J Biol Chem, 267, 19691, 10.1016/S0021-9258(18)41830-3
Asakai, 1987, Organization of the gene for human factor XI, Biochemistry, 26, 7221, 10.1021/bi00397a004
Gozzo, 2006, Heparin modulation of human plasma kallikrein on different substrates and inhibitors, Biol Chem, 387, 1129, 10.1515/BC.2006.139
Discipio, 1982, The activation of the alternative pathway C3 convertase by human plasma kallikrein, Immunology, 45, 587